Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_1
2
67%
Ph early_phase_1
1
33%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (33.3%)
Phase 12 (66.7%)

Trials by Status

recruiting267%
withdrawn133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_1

Drug Screening Using Novel IMD in Renal Cell Carcinoma

NCT05700461
recruitingearly_phase_1

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

NCT05553782
withdrawnphase_1

Implantable Microdevice for TNBC - Pilot Study

NCT05774886

Clinical Trials (3)

Showing 3 of 3 trials
NCT05700461Phase 1

Drug Screening Using Novel IMD in Renal Cell Carcinoma

Recruiting
NCT05553782Early Phase 1

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Recruiting
NCT05774886Phase 1

Implantable Microdevice for TNBC - Pilot Study

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
3